Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Appointed director
Quarterly results
Diffusion Pharmaceuticals Inc. (DFFN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/29/2023 8-K/A Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits  Interact...
Docs: " ",
" ",
" "
08/17/2023 8-K Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Changes in Registra...
Docs: " ",
" ",
" ",
" ",
" ",
" ",
" ",
"INDEMNIFICATION AGREEMENT",
" ",
" "
08/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
08/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " ",
" ",
" "
08/03/2023 8-K Other Events  Interactive Data
08/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference BOSTON, MA – August 3, 2023 – EIP Pharma Inc. , a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 4:00 p.m. ET. The Company will also be holding 1x1 meetings at the conference. A live webcast of the presentation, along with accompanying slides, can be accessed here . About EIP Pharma EIP Pharma, Inc. is a privately held clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. EIP Pharma is currently developing neflamapimod, an investigatio..."
07/31/2023 8-K Quarterly results
05/19/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Departure of Directors or Certain...
Docs: "Separation Agreement and General Release, by and between Diffusion Pharmaceuticals Inc. and William K. Hornung"
05/15/2023 8-K Investor presentation
Docs: "Corporate Presentation"
05/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EIP Pharma to Present at JMP Securities Life Sciences Conference BOSTON, MA – May 11, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET. The company will also be holding 1x1 meetings at the conference. A live webcast of the presentation, along with accompanying slides, can be accessed here, and will be available for replay for 90 days following the event. About EIP Pharma EIP Pharma, Inc. is a privately held clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. EIP Pharma is currentl..."
03/30/2023 8-K Quarterly results
12/30/2022 8-K Quarterly results
12/16/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
07/22/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/18/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to the Certificate of Incorporation, as amended, of Diffusion Pharmaceuticals Inc",
"Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan"
04/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Diffusion Pharmaceuticals Completes Dosing in Altitude Trial"
04/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders"
03/21/2022 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update ● Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO Trial ● Phase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start ● $37.3M in Cash & Cash Equivalents as of Year-End; Expected to Fund Operations Through 2023 CHARLOTTESVILLE, Va., March 21, 2022 -- Diffusion Pharmaceuticals Inc. , an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for 2021 and provided a business update. Corporate Strategy and Events Business and financial highlights during 2021 and 2022 year-to-date include: Declared Lead Dev..."
03/18/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Certificate of Designation of Preferences, Rights, and Limitations of Series C Convertible Preferred Stock",
"Amendment to the Bylaws, as amended, of Diffusion Pharmaceuticals Inc., effective March 18, 2022",
"Form of Subscription Agreement between Diffusion Pharmaceuticals Inc. and the investors named therein"
12/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial"
11/24/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Diffusion Pharmaceuticals Doses First Participants in Altitude Trial"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy